These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37552493)

  • 1. Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma.
    Singalavanija T; Ceylanoglu KS; Juntipwong S; Beser BG; Elner VM; Worden FP; Demirci H
    Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):1-10. PubMed ID: 37552493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
    Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I
    JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
    Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
    Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
    Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
    Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vismodegib for periocular and orbital basal cell carcinoma.
    Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
    JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma.
    Eiger-Moscovich M; Reich E; Tauber G; Berliner O; Priel A; Ben Simon G; Elkader AA; Yassur I
    Am J Ophthalmol; 2019 Nov; 207():62-70. PubMed ID: 31077664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
    Sagiv O; Ding S; Ferrarotto R; Glisson B; Altan M; Johnson F; Elamin Y; Thakar SD; Nagarajan P; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2019; 35(4):350-353. PubMed ID: 30365473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib for periocular basal cell carcinoma: an international multicentre case series.
    Oliphant H; Laybourne J; Chan K; Haridas A; Edmunds MR; Morris D; Clarke L; Althaus M; Norris P; Cranstoun M; Sullivan TJ; Rajak SN
    Eye (Lond); 2020 Nov; 34(11):2076-2081. PubMed ID: 31996838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma.
    Lavasidis G; Tzamalis A; Tsinopoulos I; Ziakas N
    Cancer Treat Res Commun; 2024; 39():100796. PubMed ID: 38367414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
    Sekulic A; Migden MR; Oro AE; Dirix L; Lewis KD; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Low JA; Mackey HM; Yauch RL; Graham RA; Reddy JC; Hauschild A
    N Engl J Med; 2012 Jun; 366(23):2171-9. PubMed ID: 22670903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.
    Kahana A; Unsworth SP; Andrews CA; Chan MP; Bresler SC; Bichakjian CK; Durham AB; Demirci H; Elner VM; Nelson CC; Kim DS; Joseph SS; Swiecicki PL; Worden FP
    Oncologist; 2021 Jul; 26(7):e1240-e1249. PubMed ID: 33988881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
    Mesti T; Sever M; Ocvirk J
    Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: subgroup analysis, STEVIE trial.
    Gershoni A; Tiosano A; Ben Ishai M; Barayev E; J Ben Simon G; Yassur I
    Eye (Lond); 2022 Feb; 36(2):407-413. PubMed ID: 33692538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The initial rate of tumour response to vismodegib treatment, can predict a complete response outcome for periocular LA-BCC.
    Tiosano A; Ben-Ishai M; Fenig E; Ben Simon GJ; Yassur I
    Eye (Lond); 2023 Feb; 37(3):531-536. PubMed ID: 35210571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
    Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
    J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.